Once-Weekly Semaglutide in Adults with Overweight or Obesity
Published in The New England Journal of Medicine on February 10, 2021, this study investigates the efficacy and safety of once-weekly subcutaneous semaglutide (2.4 mg) for weight loss in adults with overweight or obesity but without diabetes. Conducted as a double-blind, randomized, placebo-controlled trial, the study enrolled 1,961 participants with a body mass index (BMI) […]